Shares of AC Immune SA (ACIU) are surging over 82% in pre-market today, after the company announced the initiation of the second highest dosing group its Phase 1b/2a clinical trial evaluating ACI-35.030 for the treatment of Alzheimer's disease (AD).
from RTT - Before the Bell https://ift.tt/2WqeEEQ
via IFTTT
No comments:
Post a Comment